N/A N=43 Protonics Knee Brace Versus Hamstring Resisted Exercise (HRE) on Individuals With Patellofemoral Pain Syndrome
Patellofemoral Pain Syndrome
Primary: Anterior Pelvic Tilt — 5; 3.2 degree
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=17 Optical Frequency Domain Imaging (OFDI) Assessment in Radiofrequency Ablation
Barrett's Esophagus
Primary: Feasibility of OFDI Imaging as Determined by Number of Successful Imaging Sessions — 64; 29 Imaging sessions
Phase 2 N=84 Erlotinib in Women With Previously Untreated Adenocarcinoma of the Lung
Adenocarcinoma · Non-small Cell Lung Cancer
Primary: Overall Response Rate (ORR) — 27.7 percentage of participants
N/A N=30 Rehabilitative Trial With tDCS in Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis
Primary: Change in Muscle Strength From Baseline — 74.7; 74.7; 76.4; 74.5 units on a scale — p==0.001
N/A N=47 Females, Aging, Metabolism, and Exercise
Obesity
Primary: Change in Physical Activity Energy Expenditure (PAEE) — 74.5; -10.2; 61.0 kcal/day
Phase 2 N=35 Oral Panobinostat Adult Patients DLBCL Relapsed/Refractory Stem Cell Transfusion (ASCT) or Not Eligible for ASCT
Diffuse Large B-cell Lymphoma
Primary: Overall Response Rate (ORR) at the End of the Induction Phase — 17.1 percentage of participants
Phase 3 N=20 Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Multiple Sclerosis, Relapsing-Remitting
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 18; 2 participants
N/A N=15 Study to Investigate the Nicotine Pharmacokinetic Profiles and Pharmacodynamic Effects of P4M3 Variants
Vaping · Nicotine Absorption
Primary: Plasma Nicotine Concentration Versus Time Profile — 4.546; 3.165; 4.167; 7.518 ng/mL
N/A N=700 Clinical Validity and Utility of Genomic-targeted Chemoprevention of PCa: Aim 4a
Prostate Cancer · Prostate Cancer, Familial · Hereditary Prostate Cancer
Primary: Number of Participants Who Had Prostate Specific Antigen (PSA) Discussion With Physician at 3 Months, Measured by Survey — 34; 30; 25; 22 participants — p=0.29
Phase 2 N=47 Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies
Aggressive Non-Hodgkin Lymphoma · Blasts Under 5 Percent of Bone Marrow Nucleated Cells · Chronic Lymphocytic Leukemia
Primary: Number of Patients With Grade III-IV Acute Graft-versus-host Disease (GVHD) Post-transplant — 2; 0; 0 Participants
N/A N=3,765 Characterisation and Epidemiology of Breakthrough Cancer Pain in Spain
Breakthrough Cancer Pain
Primary: Percentage of Cancer Participants With Breakthrough Cancer Pain From the Total Number of Cancer Participants Seen in Consultation — 14.3 percentage of participants
Phase 2 N=39 Study of Combined Ionizing Radiation and Ipilimumab in Metastatic Non-small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer (NSCLC)
Primary: Therapeutic Efficacy of Anti-CTLA-4 mAb and Concurrent Local RT in NSCLC Patients With Metastatic Disease. — 7 Participants
Phase 2 N=10 Testosterone Treatment for Multiple Sclerosis
Multiple Sclerosis
Primary: Whole Brain Atrophy Rate — .82 percent change in brain volume — p=<0.05
N/A N=56 Macrophage Phagocytosis in COPD
Chronic Obstructive Pulmonary Disease · Emphysema · Chronic Bronchitis
Primary: Phagocytosis of H. Influenzae Concentration — 0.042; 0.042; 0.014; 0.06 relative fluorescence unit — p=0.05
Phase 2 N=95 Adavosertib Plus Chemotherapy in Platinum-Resistant Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Ovarian, Fallopian Tube, Peritoneal Cancer, P53 Mutation
Primary: Objective Response Rate (ORR) — 1; 11; 7; 8 Participants